Align Technology, Inc. (ALGN)

Align Technology's stock has been influenced by several events in the past six months. Strong Q4 2025 earnings led to a stock increase. Analyst upgrades and price targets also caused shares to jump. Broader market sentiment, including news of a U.S.-Iran ceasefire agreement, affected the stock. ALGN was removed from the FTSE All-World Index. Insiders have sold more company stock than they have bought. The company has been actively repurchasing shares.

Align Technology's business experiences some demand seasonality. Management expects the revenue of the Systems & Services segment to decrease in the first quarter due to seasonality. Overall profitability expectations are also related to the seasonality of the business. Average selling prices (ASPs) can fluctuate significantly quarter-over-quarter due to seasonality, product mix shifts, geographic mix shifts, and periodic promotions.

Align Technology, Inc. (ALGN) is a global medical device company specializing in orthodontic and restorative dentistry products, operating within the Healthcare sector, specifically in the Medical Devices industry. Its major products include the Invisalign system of clear aligners and iTero intraoral scanners and services, along with exocad CAD/CAM software. The Invisalign system is the most advanced clear aligner system globally and is offered in over 100 countries.

Align Technology has a significant global presence, headquartered in Tempe, Arizona, U.S. Aligners are manufactured in Juarez, Mexico, and scanners in Israel and China. Treatment plans are created in Costa Rica, and regional headquarters are in Raleigh, North Carolina (Americas), Rotkreuz, Switzerland (EMEA), and Singapore (APAC). The United States is its largest market, generating 70% of its total revenue in fiscal year 2023, while China and Europe contribute 15% and 10%, respectively.

Align Technology maintains a strong brand reputation, primarily driven by its innovative Invisalign system. The company emphasizes technology, scale, and brand as key differentiators. However, the company has faced legal challenges, including patent infringement claims against Angel Aligner. Align Technology continues to invest in technology to improve accuracy and patient outcomes.

Align Technology's ownership is predominantly institutional, with institutional investors holding 93.16% of the company's shares as of June 2025. Major institutional shareholders include The Vanguard Group, BlackRock, Inc., Capital International Investors, and State Street Corp. Individual insider ownership stood at 1.89% as of June 2025, with Joseph Lacob recognized as a significant individual shareholder.